Successful combined venetoclax to PD-1 blockade and ruxolitinib for refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.

导出 LinkOut

翻译打印收藏纠错

作者： Yue,Song ^[1] ; Xiaofei,Yang ^[1] ; Qian,Wu ^[1] ; Mengxing,Xue ^[1] ; Fei,Zhou ^[1] ; Depei,Wu ^[1] ; Suning,Chen ^[1] ; Xuefeng,He ^[1]

作者单位： National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.;Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. ^[1]

DOI 10.1111/bjh.19900

PMID 39520230

发布时间 2025-01-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

British journal of haematology

2025年206卷1期

357-360页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Successful combined venetoclax to PD-1 blockade and ruxolitinib for refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.

British journal of haematology

相似文献

British journal of haematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Successful combined venetoclax to PD-1 blockade and ruxolitinib for refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.

British journal of haematology

相似文献

British journal of haematology

相关期刊

检索历史清除